Data from genomics, transcriptomics and known treatments of non-small-cell lung cancer (NSCLC) have been combined to produce an algorithm enabling improved treatment selection for patients with NSCLC, based on underlying individual clinical characteristics of the tumour. In total, this study included the activation status of 24 'interventional nodes' which might affect treatment responses. This intervention mapping tool will be used by the WIN Consortium to conduct a prospective clinical trial in patients with metastatic NSCLC.